Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07825090 | Association of ICU Admission Time, Age Stratification, and Clinical Frailty Scale With 30-Day Mortality in Geriatric Oncology Patients | active not recruiting | — | 150 | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825207 | Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms | active not recruiting | — | 100 | Fondazione Italiana Sindromi Mielodisplastiche-ETS |
| 1 |
| Sep 17, 2026 |
| clinicaltrials |
| NCT07825519 | Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACE | active not recruiting | N/A | 252 | University Medical Center Ho Chi Minh City (UMC)OTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825766 | The Role of Total Abdominal Autonomic Nerve Preservation During the Resection of Right/Left Colon Cancer: Prospective Clinical Trial | active not recruiting | — | 200 | Fudan UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826585 | Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection | active not recruiting | Phase 1 | 6 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01061515 | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | active not recruiting | Phase 1 | 21 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01592968 | Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases | active not recruiting | Phase 3 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01629498 | Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 146 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02194387 | Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members | active not recruiting | N/A | 337 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02324387 | Tc99m Sestamibi Molecular Breast Imaging | active not recruiting | N/A | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02446236 | Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 | 27 | Hackensack Meridian HealthOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02629809 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT03028311 | Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer | active not recruiting | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03535350 | Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 36 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03624543 | CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | active not recruiting | Phase 2 | 51 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03816319 | TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 2 | Sep 16, 2026 | clinicaltrials |
| NCT03831932 | Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03955510 | Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis(AFT) | active not recruiting | N/A | 12 | Rush University Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04077099 | A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 95 | Regeneron PharmaceuticalsINDUSTRY | 3 | Sep 16, 2026 | clinicaltrials |
| NCT04119037 | Cordotomy in Reducing Pain in Patients With Advanced Cancer | active not recruiting | N/A | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04211675 | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab(STING) | active not recruiting | Phase 1 / Phase 2 | 31 | Nationwide Children's HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04390724 | Optimizing Y90 Therapy for Radiation Lobectomy | active not recruiting | — | 104 | Northwestern UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04462328 | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | active not recruiting | Phase 1 | 25 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04467021 | Cancer and Blood Pressure Management, CARISMA Study | active not recruiting | N/A | 61 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | active not recruiting | Phase 3 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04604613 | Prediction of Recurrence Among Low Risk Endometrial Cancer Patients | active not recruiting | — | 518 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04635189 | Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma | active not recruiting | Phase 2 | 28 | University of RochesterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04657081 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | active not recruiting | Phase 1 / Phase 2 | 101 | Taiho Oncology, Inc.INDUSTRY | 3 | Sep 16, 2026 | clinicaltrials |
| NCT04883242 | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 30 | University of WashingtonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04938232 | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | active not recruiting | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05165225 | Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial | active not recruiting | Phase 2 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05208944 | THIO Sequenced With Cemiplimab in Advanced NSCLC | active not recruiting | Phase 2 | 227 | Maia BiotechnologyINDUSTRY | 8 | Sep 16, 2026 | clinicaltrials |
| NCT05561595 | Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma(HEARTS) | active not recruiting | N/A | 195 | University of FloridaOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05641961 | Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care | active not recruiting | N/A | 20 | University of California, San FranciscoOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05677048 | Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | active not recruiting | N/A | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05743842 | TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning | active not recruiting | N/A | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05751668 | Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) | active not recruiting | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05763797 | Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer | active not recruiting | N/A | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05797246 | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) | active not recruiting | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05831891 | Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | RenJi HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05889195 | Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria(microDRIVE) | active not recruiting | — | 1,000 | Pacific Edge LimitedINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05944562 | Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05949944 | Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06226571 | A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | active not recruiting | Phase 1 | 96 | Syndax PharmaceuticalsINDUSTRY | 6 | Sep 16, 2026 | clinicaltrials |
| NCT06291324 | WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment | active not recruiting | — | 46 | Wake Forest University Health SciencesOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06311851 | Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases | active not recruiting | Phase 1 / Phase 2 | 40 | Pardis Noor Medical Imaging and Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06318286 | Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma(PENINSULA) | active not recruiting | Phase 2 | 25 | Hyogo Medical UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06380738 | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)(PROceed) | active not recruiting | — | 111 | AstraZenecaINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 17, 2026source: clinicaltrials